Search clinical trials for: PALB2 mutation

Total 3285 results

GenoSaber

Unknown

EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment

Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

Melanoma

United States, Belgium, Germany, Singapore, Italy, Australia, Netherlands, Sweden, Spain, Canada, Switzerland, Argentina, Brazil, China
Washington University School of Medicine

Withdrawn

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

Endometrial Neoplasms
Massachusetts General Hospital
Boston Children's Hospital

Unknown

Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia

Congenital Diaphragmatic Hernia

United States
HealthPartners Institute

Completed

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

Lung Cancer | Small Cell Carcinoma

United States
Institut National de la Santé Et de la Recherche...

Unknown

Susceptibility Genes in Autism Spectrum Disorders

Autism Spectrum Disorders

France
AstraZeneca

Completed

A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer). (REASON)

Non Small Cell Lung Cancer

Greece
University of Cincinnati
Merck Sharp & Dohme LLC

Completed

Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

Hepatitis C

United States
Memorial Sloan Kettering Cancer Center
Ascenta Therapeutics

Terminated

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Lung Cancer

United States
Samsung Medical Center

Withdrawn

Feasibility of Mutational Analysis of Non-Small Cell Lung Cancer (NSCLC) Using Low-volume Lung Aspirates

Lung Cancer

Korea, Republic of
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Melanoma

United States
Marie Luise Bisgaard, MD

Unknown

Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?

Von Hippel-Lindaus Disease

Denmark
Mclean Hospital
Brain & Behavior Research Foundation

Completed

Acute Glycine Pharmacodynamic Study

Psychotic Disorders | Schizophrenia

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
GlaxoSmithKline

Terminated

Brain Metastases In ErbB2-Positive Breast Cancer

Neoplasms, Breast

United States, Spain, Israel, Canada, Germany, Belgium, Austria, Sweden, Greece, France, Italy
Duke University
National Cancer Institute (NCI)

Completed

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

Lymphoma | Brain and Central Nervous System Tumors

United States
Bristol-Myers Squibb

Completed

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Non-Small-Cell Lung Carcinoma

Japan
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

Lung Cancer | Metastatic Cancer

United States
Boehringer Ingelheim

Completed

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Spain
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lapatinib Resistance in Patients With Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Colorectal Neoplasms

United States
National Cancer Institute (NCI)

Completed

Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes

Hamartoma Syndrome, Multiple | Cowden's Disease

United States
Hoffmann-La Roche

Completed

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms

Russian Federation, Korea, Republic of, Israel, South Africa, Belarus
Massachusetts General Hospital
Novartis Pharmaceuticals

Withdrawn

BKM120 in Cancers With PIK3CA Activating Mutations

Breast Cancer | Colorectal Cancer | Lung Cancer | Cholangiocarcinoma | Solid Tumors
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Ministero della Salute, Italy

Unknown

Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients

Desmoid-type Fibromatosis

Italy
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Non-Small Cell Lung Cancer

China
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Tongji University

Unknown

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Cystic Fibrosis

United States, Belgium, Canada, Netherlands, Germany
Medical College of Wisconsin

Withdrawn

Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease

Crohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease

United States
Kyowa Kirin Co., Ltd.

Completed

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Non-small-cell Lung Cancer

Japan
Chang Gung Memorial Hospital
Taiwan Chest Disease Association

Completed

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Advanced Non-Squamous Non-Small Cell Lung Cancer

Taiwan
University Hospital, Montpellier

Terminated

Prevalence of POU4F3 and SLC17A8 Mutations

Familial Deafness

France
Assistance Publique - Hôpitaux de Paris
France Parkinson Association

Unknown

Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET (INFLAPARK)

Healthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 Mutation

France
M.D. Anderson Cancer Center

Completed

Erlotinib in Combination With Cetuximab

Advanced Cancers

United States
M.D. Anderson Cancer Center

Completed

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Advanced Cancers

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Hepatitis | HIV/AIDS

United States
M.D. Anderson Cancer Center

Completed

Study of Erlotinib in Combination With Dasatinib

Advanced Cancer

United States
M.D. Anderson Cancer Center

Completed

Study of Erlotinib in Combination With Bortezomib

Advanced Cancer

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer
AstraZeneca
Parexel

Withdrawn

T790M Mutation Positive 2nd Line STandard of cAre Registry (T-STAR)

Non Small Cell Lung Cancer

Italy, Russian Federation, Spain, China, Netherlands, United States, Taiwan, France, Germany
Universitaire Ziekenhuizen KU Leuven

Completed

HbA2 Leuven and Its Impact on HbA1c Results (HbA2 Leuven)

Family Study HbA2 Leuven Mutation.

Belgium
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Completed

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Adult Solid Neoplasm | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Vejle Hospital
Abbott

Completed

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Ovarian Cancer

Denmark
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Non-Small Cell Lung Cancer

Finland
Universitätsklinikum Hamburg-Eppendorf

Completed

Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases

Nephrotic Syndrome | Wilms Tumor | Frasier Syndrome | Denys-Drash Syndrome

Germany

Search clinical trials for: PALB2 mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations